A new trading day began on Tuesday, with Viridian Therapeutics Inc (NASDAQ: VRDN) stock price down -5.61% from the previous day of trading, before settling in for the closing price of $16.04. VRDN’s price has ranged from $11.40 to $27.20 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -4.11% over the last five years. Meanwhile, its annual earnings per share averaged -6.05%. With a float of $73.28 million, this company’s outstanding shares have now reached $80.99 million.
The firm has a total of 143 workers. Let’s measure their productivity. In terms of profitability, gross margin is -1931.79%, operating margin of -99018.54%, and the pretax margin is -89387.09%.
Viridian Therapeutics Inc (VRDN) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Viridian Therapeutics Inc is 10.07%, while institutional ownership is 102.34%. The most recent insider transaction that took place on Sep 27 ’24, was worth 117,050. In this transaction Chief Operating Officer of this company bought 5,000 shares at a rate of $23.41, taking the stock ownership to the 6,000 shares. Before that another transaction happened on Sep 27 ’24, when Company’s President and CEO bought 21,400 for $23.33, making the entire transaction worth $499,262. This insider now owns 21,400 shares in total.
Viridian Therapeutics Inc (VRDN) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -6.05% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 23.74% during the next five years compared to 27.64% growth over the previous five years of trading.
Viridian Therapeutics Inc (NASDAQ: VRDN) Trading Performance Indicators
Here are Viridian Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 15.43. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4112.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.96, a number that is poised to hit -0.97 in the next quarter and is forecasted to reach -3.96 in one year’s time.
Technical Analysis of Viridian Therapeutics Inc (VRDN)
Analysing the last 5-days average volume posted by the [Viridian Therapeutics Inc, VRDN], we can find that recorded value of 0.55 million was lower than the volume posted last year of 1.03 million. As of the previous 9 days, the stock’s Stochastic %D was 44.87%. Additionally, its Average True Range was 0.90.
During the past 100 days, Viridian Therapeutics Inc’s (VRDN) raw stochastic average was set at 8.29%, which indicates a significant decrease from 36.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.12% in the past 14 days, which was lower than the 61.53% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.38, while its 200-day Moving Average is $17.94. Now, the first resistance to watch is $15.63. This is followed by the second major resistance level at $16.12. The third major resistance level sits at $16.40. If the price goes on to break the first support level at $14.86, it is likely to go to the next support level at $14.58. Now, if the price goes above the second support level, the third support stands at $14.09.
Viridian Therapeutics Inc (NASDAQ: VRDN) Key Stats
With a market capitalization of 1.23 billion, the company has a total of 81,485K Shares Outstanding. Currently, annual sales are 300 K while annual income is -269,950 K. The company’s previous quarter sales were 70 K while its latest quarter income was -79,730 K.
